Articles about TwinStrand Biosciences

University of Washington and Seattle biotech win $245M patent judgment against Guardant

A Seattle biotech built on University of Washington research has won a $245 million patent judgment against Guardant Health over DNA sequencing technology, with the court also ordering ongoing royalties through 2033. Read More

TwinStrand CEO and co-founder steps down from Seattle biotech startup amid reported layoffs

TwinStrand Biosciences’ co-founder Jesse Salk has stepped down from the CEO role, according to a statement issued by the Seattle… Read More

Grandson of Jonas Salk raises cash to find ‘genetic needles in the haystack’

New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based… Read More

The voters will see you now: The finalists for Health Innovation of the Year at the GeekWire Awards

The greater Seattle area is a hotbed for health technology and the past year has seen groundbreaking advancements in the… Read More

TwinStrand raises $16M from Madrona and others for next-gen DNA sequencing, promising early cancer detection and other breakthroughs

TwinStrand Biosciences, a Seattle startup developing next-generation DNA sequencing technology that promises to lead to early cancer detection, rapid identification… Read More

University of Washington spin-out raising cash for more accurate DNA sequencing technology

TwinStrand Biosciences, a spin-out of the University of Washington, is raising cash to commercialize DNA sequencing technology that it… Read More